Fibrinolytic or not : case series of stemi and deadly hemorrhagic stroke


  • Sidhi Laksono Purwowiyoto Fakultas Kedokteran Universitas Muhammadiyah Prof. Hamka
  • Steven Phillip Rumah Sakit Cijantung Kesdam Jaya



AMI, Fibrinolytic Therapy, Hemorrhagic Stroke


Cardiovascular diseases (CVD) like myocardial infraction (MI) is still becoming the leading cause of morbidity and mortality and major problem in our healthcare system. Nowadays, revolution in high-tech medical treatment alongside with well-trained staff could decrease adverse event in ST elevation myocardial infarction (STEMI) patient. However, in developing country like Indonesia, those still become a challenge. Fibrinolytic therapy is still common practice even though primary percutaneous coronary intervention (PPCI) preferred. Intracranial bleeding is one of the most unfavorable effect after fibrinolytic therapy. Clinical should aware with clinical deterioration. Here we present case series of deadly intracranial haemorrhage in STEMI patient after fibrinolytic therapy.

Author Biography

Sidhi Laksono Purwowiyoto, Fakultas Kedokteran Universitas Muhammadiyah Prof. Hamka

Divisi Kardiologi Intervensi dan Vaskuler

Dept Kardiologi dan Kedokteran Vaskuler FK UHAMKA-RSUD Pasar Rebo


[1] Dharma S, Juzar DA, Firdaus I, Soerianata S, Wardeh AJ, Jukema JW. Acute myocardial infraction system of care in the third word. Neth Heart J. 2012;20(6)2549.

[2] Danchin N. Systems of care for st-segment elevation myocardial infraction: impact of different models on clinical outcomes. JACC Cardiovasc Interv. 2009;2(10):901-8.

[3] Ibanez B, James S, Agewall S, Antunes MJ, Bucciareli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infraction in patients presenting with st-segment elevation: the task force for the management of acute myocardial infraction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.

[4] Nascimento BR, de Sousa MR, Demarqui FN, Ribeiro ALP. Risk and benefits of thrombolytic, antiplatelet, and anticoagulant therapies for st segment elevation myocardial infraction: systematic review. Int Sch Res Notices. 2014;2014:ID416253.

[5] Bundhun PK, Janoo G, Chen MH. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patient with STEMI. Medicine (Baltimore). 2016;95(23):e3877.

[6] Bairey-Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, et al. Insight from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 suppl):S21-9.

[7] Mahmood SS, LevyD, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular diseases: a historical perspective. Lancet. 2014;383(9921):999-1008.

[8] Ali SM, Rajani AR, Baslaib FA. Intracranial haemorrhage 4 days after receiving thrombolytic therapy in a young woman with myocardial infarction. BMJ Case Rep. 2013

[9] Simoons ML, Maggioni AP, Knattereud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. The Lancet Vol. 342. 1993

[10] Poli KA, Tofler GH, Larson MG et al. Association of blood pressure with fibrinolytic potential in the Framingham Offspring Population. American Heart Association. 2000

[11] MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease, II: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335:827–838.




How to Cite

Purwowiyoto, S. L., & Phillip, S. (2020). Fibrinolytic or not : case series of stemi and deadly hemorrhagic stroke. Jurnal Profesi Medika : Jurnal Kedokteran Dan Kesehatan, 14(1).